Quest Diagnostics (DGX) files 8-K: Q3 2025 results press release

Quest Diagnostics (DGX) filed an 8‑K stating it issued a press release announcing its results for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

Quest Diagnostics (DGX) filed an 8‑K stating it issued a press release announcing its results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1, dated October 21, 2025.

The filing falls under Item 2.02 (Results of Operations and Financial Condition). Quest Diagnostics’ common stock trades on the NYSE under the symbol DGX.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Quest Diagnostics (DGX) announce in this 8-K?

The company reported it issued a press release announcing results for the quarter ended September 30, 2025.

Which period does the announcement cover for DGX?

It covers the quarter ended September 30, 2025.

Where can I find the detailed results for DGX?

The detailed results are in the press release furnished as Exhibit 99.1.

What is the date of the press release for DGX?

The press release is dated October 21, 2025.

Which SEC item does this DGX filing reference?

Item 2.02: Results of Operations and Financial Condition.

What exchange and ticker does Quest Diagnostics use?

Common stock trades on the NYSE under the symbol DGX.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/21/2025 - 06:50 AM EDT Learn about SEC filing dates

0001022079false00010220792025-10-212025-10-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): October 21, 2025

Quest Diagnostics Incorporated

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or other jurisdiction of incorporation)

001-12215

16-1387862

(Commission File Number)

(I.R.S. Employer Identification No.)

500 Plaza Drive

Secaucus,

NJ

07094

(Address of principal executive offices)

(Zip Code)

(973)

520-2700

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.01 Par Value			DGX			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition

On October 21, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

d.			Exhibit
			99.1			Press release of Quest Diagnostics Incorporated dated October 21, 2025 announcing, among other things, its results for the quarter ended September 30, 2025.
			104			The cover page from this current report on Form 8-K, formatted in Inline XBRL.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

October 21, 2025

QUEST DIAGNOSTICS INCORPORATED
By:			/s/ Sean D. Mersten
			Sean D. Mersten
			Vice President and Corporate Secretary